Libtayo® (cemiplimab) approved by the european commission as the first immunotherapy in second line recurrent or metastatic cervical cancer irrespective of pd-l1 expression level or tumor histology

Approval based on a phase 3 trial that demonstrated significant survival benefit in patients with recurrent or metastatic cervical cancer, with libtayo reducing the risk of death by 31% compared to chemotherapy during the study libtayo now approved to treat four cancer types in the european union tarrytown, n.y. , nov. 22, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the european commission (ec) approved libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
REGN Ratings Summary
REGN Quant Ranking